bluebird bio, Inc. BLUE
Set alert
4.97 0.00 0.00%
At close · Jun 2
4.97 Day range 4.97
52-week range unavailable
- YTD
- -40.41%
- 1 year
- -72.25%
- Open
- 4.97
- Prev close
- 4.97
- Mkt cap
- 48.67M
- Vol
- 1.25M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.97
- High
- 4.97
- Forward P/E
- -11.98
- Beta
- 0.80
- Short ratio
- 9.53
- Inst. own
- 43.69%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 8.54
- 200-d avg
- 16.13
- 1y target
- 37.71
5Y chart
Events in this range
- Mar 29, 2023Earnings: 7.6; estimate -9; surprise 184.44%
- May 9, 2023Earnings: 4.2; estimate -10.8; surprise 138.89%
- Aug 8, 2023Earnings: -13.4; estimate -14.4; surprise 6.94%
- Aug 15, 2024Rating: B of A Securities · Buy → Buy
- Sep 13, 2024Earnings: -15.6; estimate 0; surprise —%
- Sep 16, 2024Rating: Cantor Fitzgerald · — → Neutral
- Sep 25, 2024Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Nov 14, 2024Earnings: -6.2; estimate -7.6; surprise 18.42%
- Nov 15, 2024Rating: Barclays · Overweight → Overweight
- Nov 15, 2024Downgrade: B of A Securities · Buy → Neutral
- Nov 15, 2024Rating: RBC Capital · Sector Perform → Sector Perform
- Dec 13, 2024Split: 1 for 20
Signals (53)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | May 16, 2025 | 1 year ago |
| RSI: Oversold | Mar 27, 2025 | 1 year ago |
| RSI: Oversold | Feb 27, 2025 | 1 year ago |
| SMA: Bullish | Dec 31, 2024 | 1 year ago |
| SMA: Bearish | Dec 24, 2024 | 1 year ago |
| SMA: Bullish | Dec 17, 2024 | 1 year ago |
| RSI: Oversold | Nov 19, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 14, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 16, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 29, 2024 | 2 years ago |
| SMA: Bearish | Jul 22, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| SMA: Bearish | Jul 8, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| SMA: Bearish | Apr 5, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 14, 2024 | 2 years ago |
| SMA: Bullish | Feb 29, 2024 | 2 years ago |
| MACD: Sell Signal | Dec 21, 2023 | 2 years ago |
| SMA: Bearish | Dec 14, 2023 | 2 years ago |
| SMA: Bearish | Dec 14, 2023 | 2 years ago |
| SMA: Bullish | Nov 22, 2023 | 2 years ago |
| SMA: Bullish | Nov 8, 2023 | 2 years ago |
| SMA: Bearish | Sep 12, 2023 | 3 years ago |
| SMA: Bullish | Aug 29, 2023 | 3 years ago |
| SMA: Bearish | Aug 22, 2023 | 3 years ago |
| SMA: Bullish | Jul 25, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 20, 2023 | 3 years ago |
| SMA: Bearish | Jun 13, 2023 | 3 years ago |
| SMA: Bullish | Jun 6, 2023 | 3 years ago |
| SMA: Bearish | May 16, 2023 | 3 years ago |
| SMA: Bullish | May 2, 2023 | 3 years ago |
| RSI: Oversold | Apr 4, 2023 | 3 years ago |
| SMA: Bearish | Feb 14, 2023 | 3 years ago |
| SMA: Bullish | Feb 7, 2023 | 3 years ago |
| SMA: Bearish | Jan 31, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 24, 2023 | 3 years ago |
| SMA: Bearish | Jan 17, 2023 | 3 years ago |
| SMA: Bullish | Jan 10, 2023 | 3 years ago |
| SMA: Bearish | Dec 27, 2022 | 3 years ago |
| SMA: Bullish | Oct 31, 2022 | 4 years ago |
| SMA: Bearish | Oct 24, 2022 | 4 years ago |
| SMA: Bullish | Oct 3, 2022 | 4 years ago |
| SMA: Bearish | Sep 26, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| SMA: Bearish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jun 27, 2022 | 4 years ago |
| SMA: Bearish | Jun 17, 2022 | 4 years ago |
| SMA: Bullish | Jun 13, 2022 | 4 years ago |
| RSI: Oversold | Apr 11, 2022 | 4 years ago |
Key statistics
- Market cap
- 75.74M
- Enterprise value
- 321.89M
- Trailing P/E
- 0.00
- Forward P/E
- -11.98
- PEG ratio
- 0.00
- Price / sales
- 1.38
- Price / book
- 7.72
- EPS (TTM)
- -36.00
- Beta
- 0.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 54.90M
- Revenue growth
- 133.70%
- Free cash flow
- -163.92M
- Total cash
- 144.07M
- Total debt
- 395.64M
- Return on equity
- -186.70%
- Shares outstanding
- 9.72M
- Short % of float
- 26.66%
- 50-day average
- 8.54
- 200-day average
- 16.13
Analyst view
Consensus: hold
Hold
Price target (mean) 37.71 +658.8% upside
Now 4.97
- Target (low)
- 10.00
- Target (mean)
- 37.71
- Target (high)
- 80.00
Ratings (0m) 10 2 buy · 6 hold · 2 sell
- Strong buy1
- Buy1
- Hold6
- Sell0
- Strong sell2
Next earnings
Consensus EPS estimate -5.75.
Financials — quick view
BLUE Revenue — quarterly 38.71M
BLUE Net income — quarterly -29.07M
BLUE EPS — quarterly -2.98
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -7.60 | -6.20 | +1.40 | +18.42% |
| Sep 13, 2024 | Dec 1, 2023 | 0.00 | -15.60 | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -13.80 | -13.20 | +0.60 | +4.35% |
| Aug 8, 2023 | Jun 1, 2023 | -14.40 | -13.40 | +1.00 | +6.94% |
| May 9, 2023 | Mar 1, 2023 | -10.80 | 4.20 | +15.00 | +138.89% |
| Mar 29, 2023 | Dec 1, 2022 | -9.00 | 7.60 | +16.60 | +184.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| Nov 15, 2024 | B of A Securities | down | Buy | Neutral |
| Nov 15, 2024 | Barclays | main | Overweight | Overweight |
| Sep 25, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Sep 16, 2024 | Cantor Fitzgerald | reit | — | Neutral |
| Aug 15, 2024 | B of A Securities | main | Buy | Buy |
About bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bluebirdbio.com
News
- Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
- Earnings Scheduled For November 14, 2024
- This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
- Earnings Scheduled For March 26, 2024
- Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Your note
Sign in to keep a note on BLUE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGWUNOBI JOHN O | Director | Stock Award(Grant) | Nov 5, 2024 | 51,364 |
| COLVIN RICHARD A | Officer | Sale | Dec 9, 2024 | 165,544 |
| JONES-BURTON CHARLOTTE M.D. | Director | Stock Award(Grant) | Nov 5, 2024 | 43,462 |
| LEIDERMAN ELISABETH M.D. | Director | Stock Award(Grant) | Nov 5, 2024 | 47,156 |
| LESCHLY NICK | Director | Stock Award(Grant) | Nov 5, 2024 | 484,538 |
| OBENSHAIN ANDREW | Chief Executive Officer | Sale | Dec 9, 2024 | 374,247 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 0.40% | 772,190 | 6.02M | Sep 29, 2024 |
| Vanguard Group Inc | 0.27% | 523,700 | 4.08M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.12% | 234,152 | 1.82M | Sep 29, 2024 |
| State Street Corporation | 0.10% | 192,096 | 1.50M | Sep 29, 2024 |
| FMR, LLC | 0.06% | 124,098 | 966.72K | Sep 29, 2024 |
| Avidity Partners Management, LP | 0.04% | 81,557 | 635.33K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.15% | 293,123 | 2.28M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.13% | 250,270 | 1.95M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.08% | 159,570 | 1.24M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.05% | 98,622 | 768.26K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.05% | 92,047 | 717.05K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.03% | 54,344 | 423.34K | Oct 30, 2024 |